The Indonesia pharmaceutical cold chain air logistics market size was valued at USD 142.55 million in 2025 and is estimated to grow from 154.45 million in 2026 to reach 226.41 million by 2031, at a CAGR of 7.95% during the forecast period (2026-2031). This report is segmented by Temperature Range (Chilled, Frozen, Ambient, and More), by Pharmaceutical Product Type (Small-Molecule, Biological, Specialty, Cell and Gene Therapies, Veterinary, and More), by Shipment Flow (Domestic, International), and by City (Jakarta, Surabaya, Bandung, Semarang, Denpasar, and More). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Deep-frozen and ultra-low shipments below -20 °C are forecast to grow at an 11.93 % CAGR through 2031. The category serves advanced biologics, as well as cell and gene therapies that require cryogenic handling. These medicines require specialized packaging, close temperature control, and clearly managed handoffs. FedEx stated in 2025 that its Asia-Pacific healthcare capabilities included va-Q-tainer solutions that can reach -60 °C. The Indonesia pharmaceutical cold chain air logistics market size for this category will depend on the availability of suitable airport handling and trained personnel. CEIV Pharma practices remain relevant across all temperature ranges because handling discipline is necessary in each controlled corridor.
Indonesia Pharmaceutical Cold Chain Air Logistics Market Trends and Insights
Increasing Outsourcing to GDP-Compliant Logistics Providers
The Indonesia pharmaceutical cold chain air logistics market is supported by pharmaceutical manufacturers that increasingly use specialized third-party logistics providers. These requirements are harder for smaller providers to meet across a dispersed national network. Certified operators can therefore offer a more consistent service to manufacturers with complex temperature-control needs. In March 2026, NX Group integrated PT NX Lemo Indonesia Logistik and PT Nippon Express Indonesia under its One Indonesia approach to provide a single contact point across air and ocean freight operations. This type of integration can improve response times and strengthen the position of providers that combine local execution with broader international networks.Growth of Direct-to-Patient and E-Pharmacy Fulfillment
The Indonesia pharmaceutical cold chain air logistics market is also shaped by the growth of deliveries to patients rather than only to hospitals and clinics. Insulin, fertility treatments, and selected oncology products need stable temperature conditions during delivery to remote locations. Orders in this channel are smaller and more frequent than institutional shipments, which changes packaging and dispatch requirements. Air freight can be necessary when a remote-island delivery would otherwise take several days by road or sea. B-LOG had more than 3,400 fleet units and 15 storage facilities, showing the scale being developed by domestic cold-chain providers. The channel increases demand for service models that can manage frequent deliveries without weakening temperature documentation.Archipelagic Infrastructure Gaps and High Logistics Costs
The Indonesia pharmaceutical cold chain air logistics market must serve routes that may combine air, road, smaller aircraft, and boat transport. Each transfer adds handling, packaging, scheduling, and documentation requirements. Deep-frozen shipments need dry ice or active containers, which can make handling costs 4 to 6 times higher than ambient cargo rates. This cost burden is most difficult for lower-value temperature-sensitive products, including some generics and over-the-counter biologics. Providers serving eastern routes need enough volume and route density to spread these costs while maintaining validated handling.Other drivers and restraints analyzed in the detailed report include:
- Inter-Island Air Bridges and Regional Micro-Hub Development
- CEIV-Oriented Airport Handling and Premium Shipment Integrity
- Regulatory, Customs, and Qualified-Personnel Complexity
Segment Analysis
Chilled shipments at 0 to 5 °C held 48.34% of the Indonesia pharmaceutical cold chain air logistics market share in 2025. This position reflects the large role of vaccines, insulin, and biological products that require refrigerated handling rather than frozen storage. The chilled category supports routine distribution to hospitals, clinics, and other healthcare facilities. It also aligns with the broad need for refrigerated capacity across the country’s immunization and biologics supply chains. Frozen shipments at -18 °C to 0 °C form an important secondary category for plasma protein products and selected oncology biologics. Ambient shipments support branded medicines and over-the-counter products that can move within 15 to 25 °C conditions.Deep-frozen and ultra-low shipments below -20 °C are forecast to grow at an 11.93 % CAGR through 2031. The category serves advanced biologics, as well as cell and gene therapies that require cryogenic handling. These medicines require specialized packaging, close temperature control, and clearly managed handoffs. FedEx stated in 2025 that its Asia-Pacific healthcare capabilities included va-Q-tainer solutions that can reach -60 °C. The Indonesia pharmaceutical cold chain air logistics market size for this category will depend on the availability of suitable airport handling and trained personnel. CEIV Pharma practices remain relevant across all temperature ranges because handling discipline is necessary in each controlled corridor.
Complete Report Scope:
- By Temperature Range
- Chilled (0-5 °C)
- Frozen (-18-0 °C)
- Ambient
- Deep-Frozen / Ultra-Low (Below -20 °C)
- By Pharmaceutical Product Type
- Small-Molecule Pharmaceuticals
- Branded Pharmaceuticals
- Over-the-Counter (OTC) Pharmaceuticals
- Generic Pharmaceuticals
- Biological Pharmaceuticals (Biologics, Biosimilars, Vaccines, and Blood-Derived Medicinal Products)
- Specialty Pharmaceuticals
- Cell and Gene Therapies
- Veterinary Pharmaceuticals
- Other Pharmaceutical Products
- Small-Molecule Pharmaceuticals
- By Shipment Flow
- Domestic Shipments
- International Shipments
- By City
- Jakarta
- Bandung
- Surabaya
- Medan
- Tasikmalaya
- Yogyakarta
- Semarang
- Denpasar
- Makassar
- Rest of Cities
List of Companies Covered in this Report:
- DHL Group
- Kuehne+Nagel International AG
- DSV A/S
- United Parcel Service, Inc.
- FedEx Corporation
- Cencora, Inc. (World Courier)
- CEVA Logistics
- Nippon Express Holdings, Inc.
- Yusen Logistics Co., Ltd
- LOGISTEED, Ltd
- Expeditors International of Washington, Inc.
- A.P. Moller - Maersk
- PT Jasa Angkasa Semesta Tbk
- PT Garuda Indonesia (Persero) Tbk
- PSA BDP
- Hellmann Worldwide Logistics SE & Co. KG
- KLN Logistics Group Limited
- PT Enseval Putera Megatrading Tbk
- PT Anugerah Pharmindo Lestari
- PT Kimia Farma Trading & Distribution
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET LANDSCAPE
5 MARKET SIZE AND GROWTH FORECASTS
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- DHL Group
- Kuehne+Nagel International AG
- DSV A/S
- United Parcel Service, Inc.
- FedEx Corporation
- Cencora, Inc. (World Courier)
- CEVA Logistics
- Nippon Express Holdings, Inc.
- Yusen Logistics Co., Ltd
- LOGISTEED, Ltd
- Expeditors International of Washington, Inc.
- A.P. Moller - Maersk
- PT Jasa Angkasa Semesta Tbk
- PT Garuda Indonesia (Persero) Tbk
- PSA BDP
- Hellmann Worldwide Logistics SE & Co. KG
- KLN Logistics Group Limited
- PT Enseval Putera Megatrading Tbk
- PT Anugerah Pharmindo Lestari
- PT Kimia Farma Trading & Distribution
